Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Prialt ziconotide regulatory update

As expected, ELN submitted an amendment to its NDA for Prialt ziconotide to treat severe chronic

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE